PLB1001
Phase 2Small molecule
PLB1001 is one of 95 small molecule programs targeting Glioma. It is currently in Phase 2.
3
Indications
5
Total Trials
3
Active Trials
94
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Gemzar
GGynecologic Oncology Group
Preclinical
PORTRAZZA
Eli LillyPreclinical
Vizimpro
PfizerPreclinical
Gilotrif
Boehringer IngelheimPreclinical
PLB1001
BBeijing Pearl Biotechnology Limited Liability Company
Phase 2
Ofev
Boehringer IngelheimPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Remeron
OOrganon and Co
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Glioblastoma1 trial
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Active, not recruiting·BBeijing Pearl Biotechnology Limited Liability Company·Phase 2/3·NCT06105619·84 enrolled
MET Exon 14 Mutation1 trial
Glioma1 trial
Non-Small Cell Lung Cancer1 trial
A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)
Active, not recruiting·BBeijing Pearl Biotechnology Limited Liability Company·Phase 2·NCT04258033·145 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PLB1001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details